Use of hormone replacement therapy after risk-reducing salpingo-oophorectomy.

Nora JohansenAstrid H LiavaagOle-Erik IversenAnne DørumTonje BraatenTrond M Michelsen

Published in: Acta obstetricia et gynecologica Scandinavica (2017)

Among the RRSO women and BSO controls ≤52 years old without a history of breast cancer, relatively few were current users. If there are no contraindications, these women would benefit from systemic HRT. Additionally, almost 40% of the BSO controls >52 years used systemic HRT. Doctors should be aware of this practice and prescribe systemic HRT when indicated.

Keyphrases

replacement therapy
breast cancer risk
polycystic ovary syndrome
smoking cessation
pregnancy outcomes
primary care
cervical cancer screening
pregnant women
skeletal muscle
medical students